Lam Research R&D increased by 1.7% to $583.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.9%, from $525.90M to $583.20M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 8.8% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $381.75M | $382.33M | $403.64M | $407.12M | $411.16M | $433.38M | $462.39M | $429.45M | $401.95M | $422.63M | $469.71M | $512.27M | $497.83M | $495.36M | $494.95M | $525.90M | $580.18M | $576.45M | $573.31M | $583.20M |
| QoQ Change | — | +0.2% | +5.6% | +0.9% | +1.0% | +5.4% | +6.7% | -7.1% | -6.4% | +5.1% | +11.1% | +9.1% | -2.8% | -0.5% | -0.1% | +6.3% | +10.3% | -0.6% | -0.5% | +1.7% |
| YoY Change | — | — | — | — | +7.7% | +13.4% | +14.6% | +5.5% | -2.2% | -2.5% | +1.6% | +19.3% | +23.9% | +17.2% | +5.4% | +2.7% | +16.5% | +16.4% | +15.8% | +10.9% |